Irritable bowel syndrome (IBS) and integrative medicine: clinical evidence on the efficacy of FODMAP and taxonomic phytotherapy

Nosological classification, etiopathogenesis and the PNEI axis in IBS

Irritable Bowel Syndrome (IBS) is a chronic, non-inflammatory gastrointestinal functional disorder characterized by abdominal pain or discomfort and persistent bowel habit changes (constipation, diarrhea, or alternating patterns). Classified among functional digestive disorders by the World Health Organization's International Classification of Diseases (ICD-10) and standardized according to the Rome III diagnostic criteria, IBS is clearly distinguished from inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, by the absence of macroscopically or microscopically detectable organic structural lesions and phenomena such as rectal bleeding. Affecting approximately 25% of the population in industrialized countries, with a significantly higher prevalence in females and individuals under 50 years of age, IBS accounts for over half of gastroenterology specialist consultations, profoundly impacting quality-of-life parameters (IBS-QOL).

The etiology of the syndrome is multifactorial and develops along the complex network of the psychoneuroendocrinoimmune (PNEI) system, involving the bidirectional gut-brain axis (gut-brain axis). Although abnormal intestinal motility (hyper- or hypokinesia) partially explains transit alterations, key symptoms such as flatulence and cramp-like pain are attributed to visceral hypersensitivity. Neurophysiological research highlights an increased density of afferent nerve fibers expressing transient receptor potential (TRP) and vanilloid receptors in individuals with IBS, which show pronounced hypersensitivity to physicochemical stimuli mediated by ligands such as capsaicin, menthol, and anandamide. At this level, serotonergic (5-HT) neurotransmission dysfunctions, low-grade inflammation mediated by neurogenic stimuli, mild alterations in mucosal immune function, and states of microbiota dysbiosis are also involved. The clinical diagnosis is based on the criterion of exclusion: in the absence of biochemical or anamnesic red flags, serological screening for celiac disease (anti-tTG and EMA) is recommended in diarrheic (IBS-D) or mixed (IBS-M) subtypes. Conversely, clinical evidence does not support the hypothesis that IBS is caused by common IgG-mediated "food intolerances".

Nutritional approaches and FODMAP restrictions

Conventional therapeutic intervention – based on symptomatic antispasmodics, low-dose antidepressants, or non-absorbable antibiotics – often shows limited long-term efficacy. Consequently, IBS is a leading condition for therapeutic models based on integrative medicine. In recent years, scientific attention has focused on the dietary restriction of fermentable short-chain carbohydrates, known by the acronym FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols), a category that includes fructooligosaccharides (FOS), galactooligosaccharides (GOS), lactose, fructose, and polyols (such as sorbitol and mannitol).

From a biochemical and pathophysiological perspective, unabsorbed FODMAP molecules exert a high osmotic effect in the intestinal lumen, drawing fluid into the colon. Subsequently, the resident bacterial flora rapidly anaerobically ferments these substrates, resulting in massive production of free gases. In individuals characterized by visceral hypersensitivity, the resulting mechanical distension of the intestinal walls exacerbates pain, flatulence, and diarrheic stools.

[Foods rich in FODMAP]

        ↓

[Malabsorption in the small intestine]

        ↓

[Osmotic effect in the colon] ──> Water retention ──> Diarrhea / Liquid stools

        ↓

[Rapid bacterial fermentation] ──> Gas production ──> Mechanical distension

        ↓

[Visceral hypersensitivity (TRP afferents)] ──> Pain, cramps, tenesmus

Although reducing the FODMAP load decreases fluid transit, improving diarrheic symptoms, it can induce constipation due to the concomitant reduction in prebiotic fiber intake. Metagenomic studies indicate that a prolonged, strictly FODMAP-free diet reduces total bacterial count, raises fecal pH, and significantly alters the composition of the intestinal microenvironment. To safeguard microbiota health, such restriction should be limited to a short therapeutic period (4–8 weeks) under close specialist supervision. In parallel, the clinical use of non-fermentable soluble fibers such as psyllium or psyllium husk, and the prescription of targeted probiotic strains, has proven effective in mitigating overall symptoms.

Clinical evidence of phytotherapeutic remedies in integrative therapy

Clinical phytotherapy plays a central role in the integrative treatment of IBS, harnessing the pleiotropic and synergistic action of phytocomplexes compared to isolated single molecules.

Mentha x piperita

Monographed by ESCOP guidelines and validated by the American Academy of Pediatrics, it represents the phytotherapeutic remedy with the strongest evidence of efficacy. The essential oil, rich in mono- and sesquiterpenes (including menthol), acts selectively on TRPM8 receptors located on the membranes of distal sensory neurons, exerting a powerful antispasmodic and muscle-relaxing effect on the intestinal smooth muscle by blocking calcium channels. Randomized, double-blind clinical trials conducted over periods of 4 to 8 weeks have demonstrated a significant reduction in symptom severity scores and an improvement in quality of life compared to placebo. To prevent gastrointestinal sensitivity or pyrosis, the essential oil must be administered in gastro-resistant capsules with duodenal release.

Curcuma longa

The phytocomplex extracted from the rhizome of Curcuma longa, standardized in curcuminoids (particularly curcumin, which represents approximately 5% by weight of the drug), exerts pronounced anti-inflammatory, antioxidant, and antispasmodic activities. At the molecular level, curcumin modulates the chronic inflammatory response by inhibiting the transcription factor NF-κB, thereby reducing the gene expression of TNF-α and pro-inflammatory cytokines. It also inhibits the enzyme cyclooxygenase-2 (COX-2) and lipoxygenase (LOX), blocking the conversion of arachidonic acid into inflammatory prostaglandins without causing the gastric damage typical of NSAIDs, as it does not negatively interfere with COX-1-mediated cytoprotection.

In clinical studies on IBS, daily administration of 72–144 mg of standardized Curcuma longa extract for 8 weeks resulted in a clear improvement in abdominal pain and QOL parameters in over two-thirds of the treated patients. It is essential to specify the use of the longa species: the Curcuma xanthorrhiza variant has shown inferior outcomes compared to placebo in controlled clinical trials. Classified as a GRAS (Generally Recognized As Safe) substance by the FDA and EFSA, it shows high tolerability up to 12 g/day, although medical supervision is required in individuals taking oral anticoagulants or suffering from severe cholelithiasis. The antioxidant activity also manifests at the epigenetic level through the activation of the NRF2 pathway, promoting mitochondrial biogenesis and epithelial tissue repair.

Cynara scolymus and Hypericum perforatum

Artichoke extract (Cynara scolymus) acts as a regulator of gastrointestinal motility, aiding digestion and bile flow. Post-marketing surveillance studies indicate a significant reduction in bloating and cramp-like pain in patients with IBS, thanks to the synergistic action of the phytocomplex (including cynarin and caffeoylquinic derivatives). As for St. John's wort (Hypericum perforatum), its clinical use is linked to the modulation of the psychosomatic and neurogenic component of IBS. Acting as a serotonin (5-HT) reuptake inhibitor at both the central and peripheral levels (as serotonin is a key mediator of visceral transit), the standardized hypericin extract (>0.3%) is indicated for IBS associated with anxiety-depressive syndromes. Due to the known induction of cytochrome P450 (particularly CYP3A4) and P-glycoprotein, the prescription of St. John's wort requires rigorous medical monitoring to rule out relevant drug interactions.

Galenic formulations and poly-phytocomplex synergies

The multifactorial nature of IBS justifies the high clinical efficacy of multicomponent preparations compared to monotherapies with a single plant drug. Controlled clinical trials conducted on multicentric phytotherapeutic mixtures (such as the standardized combination of nine German schoolbook plants or associations based on mint, lemon balm, and coriander) have confirmed statistically superior reductions in the IBS Symptom Scale score compared to placebo.

Guidelines and Nosological Framework (Rome IV)

·        Oka, P., et al. (2020). Global prevalence of irritable bowel syndrome according to Rome III or Rome IV criteria: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(10), 908-917.

Clinical note: The landmark study that redefined the global epidemiology of IBS by standardizing the difference in prevalence between the Rome III and the more restrictive Rome IV criteria.

·        Lacy, B. E., Pimentel, M., et al. (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology, 116(1), 17-44.

Clinical note: The American College of Gastroenterology's reference guidelines for the diagnostic exclusion approach and pharmacological and nutritional stratification.

Evidence on Low-FODMAP Diet and Gut-Brain Axis

·        Black, C. J., et al. (2022). Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut, 71(6), 1117-1126.

Clinical note: Systematic review confirming the short-term clinical superiority of the low-FODMAP diet over traditional diets in controlling flatulence and pain.

·        Van Den Houte, K., et al. (2026). Pathophysiological Mechanisms and Nonpharmacological Interventions in Irritable Bowel Syndrome: Current Insights on the Gut-Brain Axis. Neurogastroenterology & Motility, e12800.

Clinical note: Very recent study analyzing the role of TRP receptor-mediated visceral hypersensitivity and the efficacy of integrated models on the PNEI axis.

·        Rej, A., et al. (2024). The low FODMAP diet in adults with irritable bowel syndrome: clinical implementation, microbiota alterations, and long-term sustainability. Clinical Nutrition, 43(2), 312-320.

Clinical note: Metagenomic assessment of the effects of prolonged FODMAP exclusion on the pH and biodiversity of the colonic microbiota.

Clinical Phytotherapy and Standardized Phytocomplexes

·        Alammar, N., et al. (2020). The impact of peppermint oil on the Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS): a meta-analysis of randomized controlled trials. BMC Complementary Medicine and Therapies, 20(1), 21.

Clinical note: Systematic review validating the antispasmodic action of microencapsulated Mentha x piperita essential oil on the TRPM8 receptor.

·        Ng, Q. X., et al. (2022). A Systematic Review of the Clinical Efficacy and Safety of Curcuma longa Extract in Irritable Bowel Syndrome. Journal of Clinical Medicine, 11(16), 4760.

Clinical note: Molecular focus on the inhibition of NF-kB and COX-2 by pure curcumin and the clinical superiority of the longa species compared to xanthorrhiza.

·        Anheyer, D., et al. (2021). Herbal medicines for gastrointestinal disorders in adults: A systematic review of controlled clinical trials. Phytomedicine, 86, 153429.

Clinical note: International review of evidence on polyphytoextract mixtures (including Cynara scolymus and multicomponent phytocomplexes) in the regulation of gastrointestinal motility.